LIN Yiyan,DENG Yiyu.Meta⁃analysis of the effect of glucocorticoids on the prognosis of adult patients with acute respiratory distress syndrome[J].Medical Journal of Wuhan University,2025,46(02):199-204.
LIN Yiyan,DENG Yiyu.Meta⁃analysis of the effect of glucocorticoids on the prognosis of adult patients with acute respiratory distress syndrome[J].Medical Journal of Wuhan University,2025,46(02):199-204.DOI: 10.14188/j.1671-8852.2024.0499.
Meta⁃analysis of the effect of glucocorticoids on the prognosis of adult patients with acute respiratory distress syndrome
通过计算机检索PubMed、Embase、Cochrane Central Register of Controlled Trials数据库中与糖皮质激素治疗ARDS相关的随机对照试验(RCT)。检索时间段为各数据库最初时间至2024年6月1日。由2名研究者对检索结果进行整理、筛选及文献质量评价。采用Review Manager 5.4和R 4.3.2软件进行Meta分析。
To conduct a meta⁃analysis to investigate the effects of glucocorticoids on the prognosis of adult patients with acute respiratory distress syndrome (ARDS).
Methods
2
A comprehensive search was performed in PubMed
Embase
and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials (RCTs) related to glucocorticoid treatment for ARDS. The search covered studies from the inception of each database to June 1
2024. Two researchers independently screened and selected the studies and assessed their quality. Meta⁃analysis was conducted using Review Manager 5.4 and R 4.3.2 software.
Results
2
Eight studies involving 1 372 ARDS patients were included
with 720 in the glucocorticoid group and 652 in the control group. Meta⁃analysis results indicated no significant difference in the risk of 28⁃day all⁃cause mortality between the glucocorticoid group and the control group (
RR
=0.87
95%
CI
: 0.73⁃1.04
P
>
0.05). However
60⁃day all⁃cause mortality was significantly reduced (
RR
=0.77
95%
CI
: 0.61⁃0.97
P
<
0.05). Additionally
the glucocorticoid group had significantly more ventilator⁃free days at 28 d (
MD
=4.51 days
95%
CI
: 3.37⁃5.66
P
<
0.001)
a significantly lower ICU all⁃cause mortality rate (
RR
=0.55
95%
CI
: 0.40⁃0.76
P
<
0.01)
and a significantly lower in⁃hospital all⁃cause mortality rate (
RR
=0.52
95%
CI
: 0.33⁃0.81
P
<
0.01).
Conclusion
2
Glucocorticoids demonstrate certain prognostic benefits in the treatment of ARDS patients
particularly in reducing 60⁃day all⁃cause mortality
increasing the number of ventilator⁃free days at 28 d
and lowering ICU and in⁃hospital all⁃cause mortality rates. However
glucocorticoids do not significantly affect 28⁃day all⁃cause mortality.
关键词
Keywords
references
Bos L D J , Ware L B . Acute respiratory distress syndrome: Causes, pathophysiology, and phenotypes [J ] . Lancet , 2022 , 400 ( 10358 ): 1145 ⁃ 1156 .
Bellani G , Laffey J G , Pham T , et al . Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries [J ] . JAMA , 2016 , 315 ( 8 ): 788 ⁃ 800 .
Wu C M , Chen X Y , Cai YP , et al . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [J ] . JAMA Intern Med , 2020 , 180 ( 7 ): 934 .
Tzotzos S J , Fischer B , Fischer H , et al . Incidence of ARDS and outcomes in hospitalized patients with COVID⁃19: A global literature survey [J ] . Crit Care , 2020 , 24 ( 1 ): 516 .
Definition Task Force ARDS , Ranieri V M , Rubenfeld G D , et al . Acute respiratory distress syndrome: The Berlin Definition [J ] . JAMA , 2012 , 307 ( 23 ): 2526 ⁃ 2533 .
Rañó A , Agustí C , Sibila O , et al . Associated inflammatory response in pneumonia: Role of adjunctive therapy with glucocorticoids [J ] . Curr Opin Infect Dis , 2006 , 19 ( 2 ): 179 ⁃ 184 .
Clarke S A , Eng P C , Comninos A N , et al . Current challenges and future directions in the assessment of glucocorticoid status [J ] . Endocr Rev , 2024 , 45 ( 6 ): 795 ⁃ 817 .
Ashbaugh D G , Bigelow D B , Petty T L , et al . Acute respiratory distress in adults [J ] . Lancet , 1967 , 2 ( 7511 ): 319 ⁃ 323 .
Bernard G R , Artigas A , Brigham K L , et al . The American⁃European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination [J ] . Am J Respir Crit Care Med , 1994 , 149 ( 3 ): 818 ⁃ 824 .
Gu H Q , Wang Y , Li W . Application of cochrane bias risk assessment tool in meta⁃analysis of randomized controlled studies [J ] . Chin Circ J , 2014 , 29 ( 2 ): 147 ⁃ 148 .
Zeng X T , Bao C P , Cao S Y , et al . Meta⁃analysis series 3: Quality evaluation tool for randomized controlled trials [J ] . Chin J Evid Based Cardiovasc Med , 2012 , 4 ( 3 ): 183 ⁃ 185 .
Luo D H , Wan X , Liu J M , et al . Optimally estimating the sample mean from the sample size, Median, mid⁃range, and/or mid⁃quartile range [J ] . Stat Methods Med Res , 2018 , 27 ( 6 ): 1785 ⁃ 1805 .
Wan X , Wang W Q , Liu J M , et al . Estimating the sample mean and standard deviation from the sample size, Median, range and/or interquartile range [J ] . BMC Med Res Methodol , 2014 , 14 : 135 .
Bernard G R , Luce J M , Sprung C L , et al . High⁃dose corticosteroids in patients with the adult respiratory distress syndrome [J ] . N Engl J Med , 1987 , 317 ( 25 ): 1565 ⁃ 1570 .
Steinberg K P , Hudson L D , Goodman R B , et al . Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome [J ] . N Engl J Med , 2006 , 354 ( 16 ): 1671 ⁃ 1684 .
Meduri G U , Golden E , Freire A X , et al . Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial [J ] . Chest , 2007 , 131 ( 4 ): 954 ⁃ 963 .
Seam N , Meduri G U , Wang H H , et al . Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome [J ] . Crit Care Med , 2012 , 40 ( 2 ): 495 ⁃ 501 .
Tongyoo S , Permpikul C , Mongkolpun W , et al . Hydrocortisone treatment in early sepsis⁃associated acute respiratory distress syndrome: Results of a randomized controlled trial [J ] . Crit Care , 2016 , 20 ( 1 ): 329 .
Villar J , Ferrando C , Martínez D , et al . Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial [J ] . Lancet Respir Med , 2020 , 8 ( 3 ): 267 ⁃ 276 .
Tomazini B M , Maia I S , Cavalcanti A B , et al . Effect of dexamethasone on days alive and ventilator⁃free in patients with moderate or severe acute respiratory distress syndrome and COVID⁃19: The CoDEX randomized clinical trial [J ] . JAMA , 2020 , 324 ( 13 ): 1307 ⁃ 1316 .
Khan Z , Habib Khan M , Hussain S , et al . Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome [J ] . Pak J Med Health Sci , 2021 , 15 ( 8 ): 2522 ⁃ 2524 .
Hariharan A , Hakeem A R , Radhakrishnan S , et al . The role and therapeutic potential of NF⁃kappa⁃B pathway in severe COVID⁃19 patients [J ] . Inflammopharmacology , 2021 , 29 ( 1 ): 91 ⁃ 100 .
Thompson B T . Corticosteroids for Ards [J ] . Minerva Anestesiol , 2010 , 76 ( 6 ): 441 ⁃ 447 .
Matthay M A , Zemans R L , Zimmerman G A , et al . Acute respiratory distress syndrome [J ] . Nat Rev Dis Primers , 2019 , 5 ( 1 ): 18 .
Fronius M . Treatment of pulmonary edema by ENaC activators/stimulators [J ] . Curr Mol Pharmacol , 2013 , 6 ( 1 ): 13 ⁃ 27 .
Schwartze J T , Becker S , Sakkas E , et al . Glucocorticoids recruit TGFBR3 and Smad1 to shift transforming growth factor⁃β signaling from the TGFBR1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts [J ] . J Biol Chem , 2014 , 289 ( 6 ): 3262 ⁃ 3275 .